LSP has closed its LSP 6 fund at the $600m hard cap. It is the largest fund ever raised in Europe focused on life sciences ventures.
Author Archive for: TG
About Thomas Gabrielczyk
This author has yet to write their bio.Meanwhile lets just say that we are proud Thomas Gabrielczyk contributed a whooping 365 entries.
Entries by Thomas Gabrielczyk
Pest control specialist Biotalys NV has raised an additional 10m to its series C financing bringing its amount to 45m.
Researchers from German Fraunhofer IGBI have used next-generation sequencing (NGS) to diagnosis sepsis from tiny amounts of microbial DNA in the blood.
The Innovative Medicines Initiative (IMI) has announced a 45m funding for the development of therapeutics and diagnostics to tackle coronavirus outbreaks.
With the financing led by General Atlantic, the British company wants to expand a novel platform and advance its ImmTAX pipeline to the clinic.
High amounts of injected vitamin C may delay the growth of many types of tumours and boost the anticancer power of immune checkpoint therapies, report Italian oncologists.
Roche AGs has paid US$30m upfront in a potential US$1.7bn deal to get access to Bicycle Therapeutics plcs technology platform to target immune checkpoints.
Researchers at Trinity College in Dublin have demonstrated that resetting brain-specific immune cells improves traumatic brain injury (TBI) recovery.
Negotiations of the EU Council on the EU’s seven-year budget have failed, putting R&D funding at risk for significant cuts.
Royal DSM NV has entered the growing market of human milk oligosaccharides (HMO) taking over the producer of recombinant 2-fucosyl lactose, Danish Glycom A/S.